MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:02 2024-05-31 EDT | ||
| 10.73 EUR | +1.27% |
|
| 1 month | +8.51% | ||
| 3 months | +33.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 10.77 | +1.65% |
| 24-05-30 | 10.6 | +1.24% |
| 24-05-29 | 10.46 | -1.13% |
| 24-05-28 | 10.58 | +0.19% |
| 24-05-27 | 10.56 | -4.22% |
Real-time Euronext Paris
Last update May 31, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| JG9LB | |
| ISIN | NLBNPNL2H9F0 |
| Date issued | 2023-08-24 |
| Strike | 527.8 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.63 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.2 € |
|---|---|
| Lowest since issue | 2.92 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- JG9LB Certificat
